FDA in the twenty-first century : the challenges of regulating drugs and new technologies / edited by Holly Fernandez Lynch and I. Glenn Cohen.

Saved in:
Bibliographic Details
Other Authors: Lynch, Holly Fernandez (Editor), Cohen, I. Glenn (Editor)
Other title:Food and Drug Administration in the twenty-first century : the challenges of regulating drugs and new technologies.
FDA in the 21st century.
Format: Book
Published: New York : Columbia University Press, [2015]


LEADER 00000cam a2200000 i 4500
001 lb643499
003 CoU-L
005 20220526051911.0
008 150112s2015 nyu b 001 0 eng
010 |a  2015001340 
020 |a 9780231171182  |q (hardcover ;  |q alkaline paper) 
020 |a 0231171188  |q (hardcover ;  |q alkaline paper) 
035 |a (OCoLC)900159170 
035 |a .b643499x  |b lst1   |c - 
040 |a DLC  |b eng  |e rda  |c DLC  |d YDX  |d OCLCF  |d YDXCP  |d CDX  |d GZL  |d ILI  |d YULAW  |d UCX  |d UtOrBLW 
042 |a pcc 
043 |a n-us--- 
049 |a UCXA 
082 0 0 |a 363.19/20973  |2 23 
090 |a KF3871  |b .F328 2015 
245 0 0 |a FDA in the twenty-first century :  |b the challenges of regulating drugs and new technologies /  |c edited by Holly Fernandez Lynch and I. Glenn Cohen. 
246 3 |a Food and Drug Administration in the twenty-first century :  |b the challenges of regulating drugs and new technologies. 
246 1 8 |a FDA in the 21st century. 
264 1 |a New York :  |b Columbia University Press,  |c [2015] 
300 |a xii, 551 pages ;  |c 24 cm. 
336 |a text  |b txt  |2 rdacontent. 
337 |a unmediated  |b n  |2 rdamedia. 
338 |a volume  |b nc  |2 rdacarrier. 
504 |a Includes bibliographical references and index. 
505 0 |a Historical themes and developments at FDA over the past fifty years / Peter Barton Hutt -- A global and innovative regulatory environment for the U.S. FDA / Howard Sklamberg and Jennifer Devine -- FDA and the rise of the empowered patient / Lewis A. Grossman -- After the FDA : a twentieth-century agency in a postmodern world / Theodore W. Ruger -- The future of prospective medicine under the Food and Drug Administration Amendments Act of 2007 / Barbara J. Evans -- Global trends toward transparency in participant-level clinical trials data / Alla Digilova, Rebecca Li, Mark Barnes, and Barbara Bierer -- Conflicts of interest in FDA advisory committees : the paradox of multiple financial ties / Genevieve Pham-Kanter -- The crime of being in charge : executive culpability and collateral consequences / Katrice Bridges Copeland -- Recalibrating enforcement in the biomedical industry : deterrence and the primacy of protecting the public health / Patrick O'Leary -- Prospects for regulation of off-label drug promotion in an era of expanding commercial speech protection / Aaron S. Kesselheim and Michelle M. Mello -- The FDCA as the test for truth of promotional claims / Christopher Robertson -- Why FDA's ban on off-label promotion violates the First Amendment : a study in the values of commercial speech protection / Coleen Klasmeier and Martin H. Redish -- Speed versus safety in drug development / R. Alta Charo -- Overcoming "premarket syndrome" : promoting better postmarket surveillance in an evolving drug development context / Shannon Gibson and Trudo Lemmens -- FDA's Public Health Imperative : an increased role for active postmarket analysis / Efthimios Parasidis -- The drug efficacy study and its manifold legacies / Daniel Carpenter, Jeremy Greene, and Susan Moffitt -- Drug safety communication : the evolving environment / Geoffrey Levitt -- Innovation policy failures in the manufacturing of drugs / W. Nicholson Price II -- From "recycled molecule" to orphan drug : lessons from Makena / Kate Greenwood -- FDA, negotiated rule making, and generics : a proposal / Marie Boyd -- The "follow-on" challenge : statutory exclusivities and patent dances / Arti Rai -- FDA regulation of biosimilars / Henry Grabowski and Erika Lietzan -- Analog agency in a digital world / Nathan Cortez -- Twenty-first-century technology with twentieth-century baggage : FDA regulation of regenerative medicine / Margaret Foster Riley -- Device-ive maneuvers : FDA's risk assessment of bifurcated direct-to-consumer genetic testing / Elizabeth R. Pike and Kayte Spector-Bagdady -- A new regulatory function for e-prescriptions : linking FDA to physicians and patient records / Andrew English, David Rosenberg, and Huaou Yan -- Race and the FDA / Jonathan Kahn. 
610 1 0 |a United States.  |b Food and Drug Administration. 
650 0 |a Drugs  |x Law and legislation  |z United States. 
610 1 7 |a United States.  |b Food and Drug Administration.  |2 fast  |0 (OCoLC)fst00549734. 
650 7 |a Drugs  |x Law and legislation.  |2 fast  |0 (OCoLC)fst00898830. 
651 7 |a United States.  |2 fast  |0 (OCoLC)fst01204155. 
700 1 |a Lynch, Holly Fernandez,  |e editor. 
700 1 |a Cohen, I. Glenn,  |e editor. 
902 |a 220722 
999 |b 1  |c 151027  |d m  |e a  |f -  |g 0 
994 |a lst1 
945 |l lst1  
999 f f |i 27fc1b07-2bfd-515d-b122-c568823448b1  |s 793245fb-35e1-575a-8893-56fec32addbb 
952 f f |p Can circulate  |a University of Colorado Boulder  |b Law Campus  |c Law  |d Law Library - Stacks 1st floor  |e KF3871 .F328 2015  |h Library of Congress classification  |i book  |m U182004815229  |n 1